Abstract
The phosphoinositide 3-kinase (PI 3-kinase, PI3K) pathway transduces signals critical for lymphocyte function. PI3K generates the phospholipid PIP3 at the plasma membrane to recruit proteins that contain pleckstrin homology (PH) domains – a conserved domain found in hundreds of mammalian proteins. PH domain–PIP3 interactions allow for rapid signal propagation and confer a spatial component to these signals. The kinases Akt and Itk are key PI3K effectors that bind PIP3 via their PH domains and mediate vital processes – such as survival, activation, and differentiation – in lymphocytes. Here, we review the roles and regulation of PI3K signaling in lymphocytes with a specific emphasis on Akt and Itk. We also discuss these and other PH domain-containing proteins as they relate more broadly to immune cell function. Finally, we highlight the emerging view of PH domains as multifunctional protein domains that often bind both lipid and protein substrates to exert their effects.
Keywords: PI3K, lymphocyte activation, pleckstrin homology domain, Akt signaling, Itk signaling
Lymphocyte Activation Receptors Signal through Class I PI3Ks
Phosphoinositide 3-kinase (PI3K) activation is important for lymphocyte survival, activation, differentiation, and migration. Many lymphocyte surface receptors activate class 1 PI3Ks, which phosphorylate phosphatidyl inositol 4,5-bisphosphate [PI(4,5)P2, PIP2] at the D-3 hydroxyl group of the myo-inositol ring to generate phosphatidyl inositol 3,4,5-trisphosphate [PI(3,4,5)P3, PIP3]. Two subclasses, 1A and 1B, are activated by distinct receptor types (Figure 1). Receptors or signaling adapters that are phosphorylated at YxxM sequence motifs signal though class IA PI3K, which includes p85α and p85β regulatory subunits and p110α, p110β, and p110δ catalytic subunits. These receptors include CD19, CD28, and ICOS co-receptors; IL-2, IL-7, IL-3, IL-15, and GM-CSF cytokine receptors (1–6); and receptors coupled to TRIM, DAP10, and MyD88 adapter proteins (7–11). Receptor ligation leads to tyrosine phosphorylation at the YxxM motif and subsequent recruitment of PI3K regulatory subunits through one or both Src homology 2 (SH2) domains. Regulatory subunits are then phosphorylated by Syk or Jak family tyrosine kinases to trigger activation of their constitutively associated catalytic subunits (3).
G-protein-coupled receptors (GPCRs) signal through Class 1B PI3K, which includes p101 regulatory and p110γ catalytic subunits (12). These classic, seven transmembrane domain receptors include chemokine receptors and signal through heterotrimeric G proteins, Gα and Gβγ to promote cell migration. GPCR ligation dissociates the Gβγ dimer, allowing its binding to p101 regulatory subunits and subsequent activation of associated p110γ catalytic subunits. Activation of p110γ catalytic activity can also be induced by Ras activation (Ras-GTP) to promote migration of neutrophils (13).
Although many receptors activate class 1 PI3K, the magnitude and kinetics of PI3K activation differs greatly among receptors, depending on ligand binding kinetics and feedback circuitry that can either amplify or dampen PI3K signaling (14). Additionally, co-ligation of receptors, such as the T cell receptor (TCR) and the CD28 co-receptor, can cooperate to potentiate and sustain PI3K activation and PIP3 generation.
PIP3 Association with Pleckstrin Homology Domains
PI3K activation induces PIP3 accumulation, which comprises less than 5% of PIP2 levels and less than 1% of total membrane lipids (15). Despite its low overall abundance, super-resolution microscopy has revealed ~100 nm membrane clusters of PIP3 that create high local PIP3 concentrations (16). High affinity and specificity binding between PIP3 and pleckstrin homology (PH) domains of PI3K effectors helps to recruit and activate these effectors at the plasma membrane (Figure 2). Like protein–protein interactions that are induced by phosphorylation, PIP3 interactions with PH domains allow rapid transduction of downstream signals without new protein synthesis.
The PH domain is an evolutionarily conserved structural fold found in proteins expressed in organisms ranging from yeast to mammals (17). The core of the PH domain is a seven-strand β-barrel that is encoded by approximately 120 amino acids and is composed of two anti-parallel β sheets and a C-terminal α helix (Figure 3). The mammalian genome contains roughly 300 PH domains found in proteins that perform diverse functions including cellular activation, cytoskeletal reorganization, vesicular trafficking, and cell cycle control. Approximately, 15% of PH domains, including Akt and Itk, bind to phosphoinositides with high specificity and affinity (Kd: nanomolar – low micromolar range). PH domains generally interact with phosphoinositides through positively charged lysine and arginine residues within the basic motif KXn(K/R)XR (18). However, not all PH domains bind to PIP3. Several PH domains interact with phosphoinositides that are selectively enriched in other membrane compartments, such as PI4P within the Golgi membrane (19) or PIP2 at the resting plasma membrane (17). Thus, conveying lipid specificity to PH domains constitutes a key mechanism for spatially sequestering distinct effector proteins within cells. Regulating the abundance of lipids either in resting or activated cells controls basal and induced effector activity. Additionally, regulated production of lipid ligands such as PIP3 within specific membrane nano-domains can induce polarized activation of downstream effectors in a robust but transient manner. This is because PIP3 abundance is not only spatial restricted but also finely controlled by receptor-induced PI3K-dependent PIP3 generation and by phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and SH2 domain-containing inositol 5′-phosphatase (SHIP) phosphatase-dependent PIP3 metabolism.
Protein Phosphatases Inhibit PI3K Activation While Inositol Phosphatases Reduce PIP3 Levels
PI3K signaling is negatively regulated at distinct steps in its signaling cascade by both protein and lipid phosphatases. Protein tyrosine phosphatases SHP-1 and SHP-2 inhibit PI3K activation by preventing early receptor signaling and by directly down-regulating PI3K activity, the latter of which is accomplished by de-phosphorylation of phospho-tyrosine residues within signal adapter proteins and PI3K regulatory subunits (71). Inhibitory receptors that restrict lymphocyte activation through SHP-1 or SHP-2 include inhibitory killer-cell immunoglobulin-like receptors (KIR) on NK cells (72), CD22 on B cells (73), and CTLA-4 and PD-1 on T cells (74, 75). Phosphorylated immunoreceptor tyrosine-based inhibition motifs (ITIM) within the cytoplasmic domains of KIRs, CD22, and CTLA-4 recruit SHP-1 and SHP-2 to prevent activating signals at the plasma membrane (72, 74, 75). Persistent T cell activation signals can also be inhibited by SHP-1 and SHP-2 recruitment to the immunoreceptor tyrosine-based switch motif (ITSM) in PD-1, an inhibitory receptor expressed on chronically stimulated T cells (76, 77). For a detailed discussion regarding the requirements of SHP-1 and SHP-2 in T cell development, differentiation, and effector function, refer to Ref. (78).
In T cells, CTLA-4 can also directly repress Akt signaling by recruiting the Ser/Thr phosphatase PP2A (77), which dephosphorylates the T308 (79, 80) and possibly S473 (79), residues required for Akt activity. Thus, CTLA-4 utilizes a dual approach to antagonize CD28 and PI3K signaling: SHP-2-dependent inhibition of TCR signaling by CD3ε de-phosphorylation and PP2A-dependent de-phosphorylation of Akt (74, 77, 81).
Lipid and inositol phosphatases also prevent PI3K effector activation. PTEN and SHIP both dephosphorylate membrane PIP3. However, while PTEN converts PIP3 back to its lipid precursor PI(4,5)P2 to prevent further activation of PI3K effectors, SHIP converts PIP3 into PI(3,4)P2, a lipid that retains the ability to bind the Akt PH domain (82). In the latter case, subsequent de-phosphorylation of PI(3,4)P2 into PI(3)P by the inositol phosphatase, INPP4B is required to “turn off” Akt membrane recruitment (83). Inhibitory receptors including FcγIIB on B cells and mast cells and Ly49A and Ly49C on NK cells contain ITIM motifs that recruit SHIP through its SH2 domain (84, 85). Membrane receptors with cytosolic PDZ domains recruit PTEN to control PIP3 levels. Although the functional significance of PDZ domain-containing receptors on lymphocyte activation requires additional investigation, maintaining appropriate PTEN levels is crucial for the control of immune cell homeostasis and function (86).
General and Cell Type-Specific Akt Functions
Akt belongs to the AGC family of Serine/Threonine kinases. The three Akt isoforms are differentially expressed in various cell types but are 77–83% sequence identical. Akt activity prevents apoptosis, promotes protein expression, and regulates cellular metabolism (20–23). Akt mediates these general cellular functions through direct phosphorylation of RxRxxS*/T* motifs (24) found in a plethora of cellular targets including forkhead box transcription factors, TSC2, GSK3, and BAD, which are discussed in detail elsewhere (20). A somatic mutation in Akt that replaces glutamate with lysine at residue 17 (hereafter referred to as E17K) leads to cellular transformation and has been identified in human breast, colorectal, and ovarian cancer (25, 26). The E17K mutation is located in the lipid binding pocket of Akt’s PH domain and dramatically increases its affinity for membrane lipids, causing constitutive Akt signaling (27). Ectopic expression of E17K in hematopoietic stem cells is sufficient to induce development of lymphoblastic T cell lymphoma within 6–8 weeks following transfer into recipient mice (28). Similarly, conditional deletion of the Akt targets Foxo1/3/4 in mice leads to development of the same type of lymphomas 15–25 weeks after induction of Foxo deletion (29).
In lymphocytes, Foxo proteins regulate the gene expression of Rag recombinases, Ikaros, CCR7, IL-7R, TCF7, Eomes, and Foxp3, which are critical for controlling lymphocyte development, trafficking, and differentiation (30–37). Akt phosphorylation of Foxo1 and Foxo3 leads to their degradation and down-regulates Foxo-dependent gene expression (31, 38). Genetic ablation of both Foxo1 and Foxo3 causes a multi-focal autoimmune disease due to defective Foxp3 expression and T regulatory (Treg) cell specification and function (34). Similarly, retroviral expression of constitutively active myristoylated Akt (myrAkt) in CD4−CD8− thymocytes impairs Treg development in vivo following intrathymic transfer. Importantly, the inhibitory effect of myrAkt is on de novo but not established Foxp3 expression (39). In contrast, broad expression of myrAkt as a transgene under the control of the CD2 promoter leads to increased regulatory T cell numbers in vivo and enhanced suppressive activity (40). Interestingly, conventional CD4+ T cells expressing transgenic myrAkt are less responsive to TGFβ suppression and fail to differentiate into the Th17 lineage in response to TGFβ and IL-6 in vitro (40).
A proper balance of Akt activity is also required for appropriate CD8+ T cell maturation, effector function, and memory development (41). Uzel and colleagues recently published a study on patients with somatic dominant active p110δ (a catalytic subunit of PI3K) expression (42). T cell blasts from these patients have increased phosphorylation of AKT at T308 and S473, a decline in Foxo1, increased S6 activation, and glucose uptake. This hyperactive Akt/mTORC1 axis causes CD8 T cells to proliferate more vigorously, differentiate more readily into effector cells, and undergo cellular senescence. Sustained Akt activity in these patients also impairs development of CD8 memory T cells, which require a metabolic “switch” from glycolysis to fatty acid oxidation (41, 43). Furthermore, defective CD8 responses result in recurrent sinopulmonary infections and chronic viremia due to Epstein-Barr virus (EBV) and/or cytomegalovirus (CMV) infection (42). Cantrell and coworkers published a surprising finding demonstrating distinct roles for PDK1 and Akt in promoting cellular metabolism and effector responses of CD8 T cells, respectively (44). T cells expressing a catalytically inactive p110δ or treated with an Akt inhibitor are defective for Akt T308 phosphorylation. Akt-defective CD8 T cells proliferate normally in response to IL-2 but are unable to express proper lymphoid homing receptors and cytotoxic effector proteins (44). In contrast, conditional deletion of PDK1, the upstream activator of Akt, leads to defective glucose uptake and metabolism, resulting in reduced CD8 T cell proliferation. This indicates that PDK1 promotes proliferation in an Akt-independent manner (44). It remains to be determined whether PDK1 and Akt have distinct roles in cell types in which multiple functions have been attributed to Akt activity.
Tec Family Kinases Regulate Immune Cell Development and Function
The Tec family of non-receptor tyrosine kinases, including Tec, Btk, Itk/Emt/Tsk, Rlk/Txk, and Bmx/Etk, are differentially expressed in immune cells. Each Tec family member contains an N-terminal PIP3-binding PH domain except Rlk, which contains a cysteine-string motif that results in Rlk palmitoylation. In general, Tec kinases activate PLCγ to trigger Ca2+ and diacylglycerol (DAG) signaling. Mimicking Ca2+ and DAG activation with the addition of calcium ionophores and phorbol myristate acetate (PMA) is sufficient to induce many aspects of lymphocyte activation, differentiation, and effector responses in vitro. The requirement for Tec kinases in immune functions is apparent from the profound defects observed in human patients carrying mutations in Tec kinases and in mouse models of single and combined Tec kinase deficiencies.
In 1993, Btk was first identified in patients with X-linked agammaglobulinemia (XLA), an inherited immunodeficiency disease characterized by profound hypogammaglobulinemia due to severely decreased B cell numbers (45). XLA patients carry Btk mutations that prevent the maturation of pro-B cells into pre-B cells. Pre-B-cell receptor signaling at the pro-B to pre-B transition requires Btk activation by the Src kinase Lyn (46–48). A Btk mutation database generated from approximately 400 XLA patients indicates that the majority of missense mutations in the Btk PH domain are in the putative PIP3-binding pocket (49–51). The XLA missense mutants F25S, R28H, T33P, V64F, and V113D dramatically reduce Btk binding to PIP3 in vitro and disrupt Btk activation in B cells (52, 53). A similar mutation in mice, R28C also abolishes Btk binding to PIP3 and results in murine X-linked immunodeficiency (Xid) disease (53). These findings demonstrate the importance of PI3K-dependent PIP3 generation for the membrane recruitment and activation of Btk in promoting B cell receptor signaling during maturation and humoral immune responses.
While disruption of PIP3 association causes hypo-B-cell responses, enhanced PIP3 association also leads to B cell dysfunction. The Btk E41K mutant significantly increases Btk PH domain affinity for phosphoinositides and results in constitutive membrane localization when expressed ectopically in COS-7 cells (52, 53). Btk E41K expression allows cytokine-independent growth of the pro-B-cell line Y16 (54), demonstrating its gain-of-function activity. However, mice expressing a Btk E41K transgene controlled by the MHC class II locus are more severely B cell-deficient than even Xid mice (55). Lack of IgMhigh cells in the bone marrow suggest that constitutive Btk E41K activation leads to inappropriate deletion of immature B cells by mimicking strong BCR signals that promote apoptosis of auto-reactive B cells (55). Thus, appropriate levels of Btk activation are critical for developmental progression of B cells, productive B cell activation and differentiation, as well as deletion of auto-reactive cells.
The first patients identified with Itk mutations were initially diagnosed with Hodgkin’s lymphoma but subsequently characterized to have an underlying immunodeficiency disease that prevents control of EBV-induced B cell proliferation (56). Itk-deficient patients have decreased T cells (57), which are required to control EBV infection and prevent viral reactivation from latently infected B cells (58). Detailed characterization of Itk-deficient mice reveals multiple requirements for Itk during T cell development, differentiation, and function (59, 60). Like Btk in B cells, Itk participates in proximal antigen receptor signaling and is directly phosphorylated by a Src family kinase, in this case Lck (61). Activated Itk phosphorylates PLCγ1, which induces IP3-dependent increased intracellular Ca2+ levels as well as DAG-mediated signaling (59, 62, 63). Itk is required for efficient CD4+ T cell differentiation toward the Th2 and Th17 lineages (59). Itk-deficient mice cannot generate protective Th2 responses in multiple infection models, including Leishmania major, Nippostrongylus brasiliensis, and Schistosoma mansoni (59, 64). Defective Th2 differentiation is accompanied by substantially reduced production of the Th2 cytokines IL-4, IL-5, and IL-13 by Itk-deficient T cells (65, 66). Itk is also required for optimal production of the Th17 cytokine, IL-17A but not IL-17F (67). The selective requirement for Itk in IL-17A production is mechanistically linked to a requirement for the transcription factor nuclear factor of activated T cells (NFAT) in IL-17A transcription (64, 67, 68). Prolonged Itk activation maintains cytosolic Ca2+ levels to promote sustained calcineurin-dependent NFAT nuclear translocation. Itk deficiency or suboptimal TCR signaling restricts autoimmunity by biasing T cell differentiation from the Th17 toward the regulatory T cell lineage (69). In addition, autoimmune organ destruction can be limited by Itk-dependent control of transendothelial migration and tissue infiltration of effector T cells (70). Thus, mechanisms that regulate the magnitude and kinetics of Itk activity in T cells are important for induction of effector functions, specification of appropriate T cell lineages, and control of T cell trafficking.
Soluble Analogs of PIP3 Differentially Regulate PIP3 Effectors
Some PIP3-binding PH domains can associate with soluble PIP3 analogs. These include the cytosolic inositol phosphates Ins(1,3,4,5)P4 (IP4), Ins(1,2,3,4,5,6)P6 (IP6), and 5-PP-I(1,2,3,4,6)P5 (IP7) that are generated inducibly or constitutively by distinct inositol kinases (82). The effect of IP4, IP6, and IP7 binding is distinct for different PH domains and cell types (Figure 4).
The inositol kinases IP3 kinase (Itpk) isoforms A, B, and C, and inositol polyphosphate multikinase (IPMK) can each generate IP4 by phosphorylating Ins(1,4,5)P3 (IP3) at the D-3 hydroxyl group [reviewed in Ref. (87)]. However, mice deficient in the ubiquitously expressed ItpkC or IPMK isoforms or in the neuronally enriched ItpkA isoform have no detectable immune abnormalities. In contrast, ItpkB expression is selectively enriched in hematopoietic cells and catalytically activated by the Ca2+-sensing protein calmodulin (CaM) following antigen receptor signaling. Analysis of ItpkB-deficient mice revealed a non-redundant requirement for ItpkB in lymphocyte development and activation (88–92). ItpkB deficiency results in severely reduced peripheral T cell numbers due to an absolute block in positive selection of CD4+CD8+ thymocytes (88). Defective activation of the Ras/MAP kinase pathway contributes to the T cell developmental defect (88, 89, 93). However, ItpkB-deficient CD4+CD8+ thymocytes are also defective in activation of Itk and its downstream effector PLC γ1 in response to TCR engagement (93). Itk fails to localize to the plasma membrane or assemble with the adapter protein LAT in the TCR signalosome of ItpkB-deficient thymocytes, indicating a requirement for IP4 in promoting Itk interactions (93). Interestingly, addition of IP4 increases binding of recombinant Itk PH domain to PIP3-coated beads in vitro, suggesting that IP4 may alter Itk PH domain conformation to enhance PIP3 accessibility (93).
Distinct from its effect on Itk, IP4 suppresses Akt activity by directly competing with PIP3 for binding to the Akt PH domain (94). ItpkB-deficient mice develop profound alterations in neutrophil and NK cell functions due to enhanced Akt activity during their development and activation (94, 95). Addition of membrane permeable IP4, but not an isomer, to the myeloid cell line HL-60 disrupts membrane localization of an Akt PH domain fused to GFP (94). In ItpkB-deficient neutrophils, Akt phosphorylation is enhanced in response to the bacterial peptide Formyl–Methionyl–Leucyl–Phenylalanine (fMLP). Enhanced Akt signaling in ItpkB-deficient neutrophils contributes to augmented anti-microbial and chemotaxis responses (94). The magnitude and kinetics of Akt phosphorylation are also increased in ItpkB-deficient NK cells (95). Elevated IFNγ secretion, granule exocytosis, and tumor cell lysis by ItpkB-deficient NK cells can be suppressed by Akt inhibition (95). Together, these studies indicate that IP4 dampens Akt activity in neutrophils and NK cells to restrict effector functions. Whether this occurs to shut-off innate functions during the resolution phase of an immune response or as a check to limit inflammatory damage remains unclear.
Similar to IP4, IP7 also competes with PIP3 for binding to the Akt PH domain and negatively regulates its activity (96). IP7 is generated by pyro-phosphorylation of IP6 at the 5-phosphate group by IP6 family kinases, IP6Ks (97, 98). While the importance of IP6K1 in lymphocyte function remains to be determined, analysis of IP6K1-deficient neutrophils demonstrates similar functional defects as ItpkB-deficient neutrophils. Both deficiencies result in enhanced fMLP-induced chemotaxis, superoxide production, and bacterial killing (94, 99). Akt membrane localization and activation are significantly increased in IP6K1-deficient neutrophils (99). Interestingly, IP7 is readily detectable in resting HL-60 cells but rapidly decreases upon fMLP stimulation (99). This suggests that IP7 may act to suppress initial Akt activation while IP4 regulates subsequent Akt activity following its induced production. Precise regulation of basal and induced IP4 and IP7 levels may act together to control the magnitude and kinetics of Akt activation in these innate immune cells. Future studies are required to determine the functional effects of IP4 and IP7 on Akt-dependent regulation of lymphocyte differentiation and effector responses. It also remains to be determined whether IP7 acts on other PIP3 effectors in immune cells as it does in Dictyostelium discoideum (100) or whether selective IP7 binding allows regulation of a particular subset of PIP3 effectors.
Recently, biochemical and structural analyses of Btk identified a new activating function for the inositol phosphate, IP6 (101). As with PIP3-containing liposomes, addition of soluble IP6 induces Btk trans-phosphorylation and activation. However, IP6 promotes Btk activation by an unconventional mechanism that is independent of the PIP3-binding pocket and membrane recruitment. Analysis of the co-crystal structure of IP6 with the Btk PH domain reveals an additional peripheral IP6 binding site sandwiched between two PH modules, termed the Saraste dimer. Molecular dynamics simulations suggest that IP6 neutralizes electrostatic forces in the monomer that oppose dimer formation. Mutation of the IP6 peripheral binding site disrupts transient dimerization and significantly abrogates IP6-dependent Btk trans-phosphorylation (101). IP6-induced Btk activation in solution represents a new PI3K-independent mechanism for controlling Btk activity. Considering that IP6 levels are basally high in lymphocytes, it will be important in future studies to determine whether IP6 contributes to tonic or B cell receptor-induced Btk function.
Proteins Interact with and Regulate the Activity of PH Domain-Containing Proteins
Although the Akt and Itk PH domains specifically bind to PIP3 with (nanomolar) affinities, only ~40 mammalian PH domains appear to be PIP3-regulated according to Teruel and colleagues, who developed a prediction algorithm based on experimental analyses of 130 mouse PH domains (102). The majority of PH domains do not interact with lipids or bind lipids promiscuously or with low affinity (Kd ≥ 10 μM). Furthermore, a growing number of PH domains have been reported to participate in inter- and/or intra-molecular protein interactions (discussed below). These findings support a revised view of PH domains as diverse, multifunctional domains that bind lipids, proteins, or both to regulate the activity of their parent proteins.
T and B cells induce Ca2+ and DAG-mediated signaling through PLCγ1- and PLCγ2-mediated cleavage of PIP2 (103, 104). T cell-specific ablation of PLCγ1 causes defects in thymocyte selection during T cell development, reduced T cell proliferation and cytokine secretion, and the development of autoimmunity resulting from defective regulatory T cells (104). PLCγ2 plays important roles in regulating B cells, neutrophils, mast cells, and dendritic cells (105–107). PLCγ1 and PLCγ2 both contain two PH domains. The conventional, N-terminal PH domain associates with PIP3 (108); however, the C-terminal PH domain is interrupted by an intervening amino acid sequence comprising two tandem SH2 domains and an SH3 domain (109, 110). This split PH domain is also critical for substrate binding (111). The C-terminal half of the PLCγ1 split PH domain associates with a partial PH domain in TRPC3 (112, 113), a Ca2+ channel that can mediate Ca2+ entry in T cells. The formation of this inter-molecular PH-like domain allows PLCγ1 to bind to its substrate PIP2 and is critical for TRPC3 membrane targeting and surface expression (113). Conversely, the split PH domain of PLCγ2 interacts with the small GTPase Rac2, which mediates PLCγ2 activation and localization to the plasma membrane (114–116).
Pleckstrin homology domains also participate in intra-molecular interactions. In resting cells, the Akt PH domain associates with the kinase domain (KD) to maintain a closed conformation in which the activation loop is blocked (117, 118). PIP3 binding to the Akt PH domain exposes the activation loop, allowing T308 and S473 to be accessed and phosphorylated by PDK1 and mTORC2, respectively (119). Phosphorylation of T308 and S473 fully activates Akt and keeps the activation loop “open” for substrate docking (117–119). PH domain mutations that disrupt PH–KD interaction (e.g., L52R and Q79K) result in constitutive Akt activation (119).
The Dbl family RhoGEF Vav is also regulated by lipid and intra-molecular interactions involving its PH domain (Figure 5). Vav plays crucial roles during T cell and B cell development (120, 121) and T cell, B cell, neutrophil, and NK cell activation (9, 107, 120–123). Vav contains a Dbl homology (DH) domain that promotes the activation of the small GTPase Rac in response to PI3K activation (124, 125). In quiescent cells, Vav1 adopts an auto-inhibitory conformation, which is stabilized by interactions between its PH, acidic (Ac), and calponin homology (CH) domains (126, 127). A truncation mutation of the Vav N-terminal CH domain was shown to have oncogenic potential (128), highlighting the importance of these intra-molecular interactions in limiting Vav activity. During T cell activation, Lck phosphorylates tyrosine residues within the Ac domain to release Vav1 from auto-inhibition (127). PIP3 binding to the PH domain significantly enhances Lck-dependent Vav1 phosphorylation in vitro (129) and promotes GEF activity (124, 129, 130) likely through the release of auto-inhibition (131). Interestingly, PIP2 binding to the Vav1 PH domain inhibits GEF activity (129). Thus, distinct lipids bind to the Vav1 PH domain to promote conformational changes that either reinforce or relieve its auto-inhibitory state.
Pleckstrin homology domains can also participate in inter-molecular interactions with other proteins. The PH domain of Dbs, a Cdc42/RhoGEF, associates with Cdc42 through the β3/β4 loop of its PH domain to improve substrate docking and catalysis (132). Interestingly, we recently identified the β3/β4 loop of the Itk PH domain as an important binding site for the ubiquitous Ca2+-sensing protein CaM (133). The CaM C-terminal EF hands bind to the β3/β4 loop of the Itk PH domain at basal intracellular Ca2+ levels while the CaM N-terminal EF hands engage the β5/β6 loop upon an increase in Ca2+ levels. CaM and PIP3 (but not IP4) reciprocally enhance binding of one another to the Itk PH domain in vitro, suggesting that CaM and PIP3 cooperate to regulate Itk signaling at the plasma membrane. Pharmacological inhibition of Ca2+/CaM activity or mutation of the CaM-binding β3/β4 loop disrupts Itk-dependent activation of PLCγ1 and downstream Ca2+ responses (133), indicating that CaM participates in a positive feedback loop whereby binding of CaM to the Itk PH domain enhances further Itk activation and downstream Ca2+ responses. Importantly, this positive feedback is required for optimal TCR-induced, NFAT-dependent production of the pro-inflammatory cytokine, IL-17A (133). Thus, CaM represents a novel protein-binding partner for the Itk PH domain that serves an important function in potentiating T cell pro-inflammatory responses (Figure 6). It remains to be determined how CaM, PIP3, and IP4 coordinate to regulate the kinetics and magnitude of Itk activation and whether they differentially participate in Itk-dependent T cell activation, differentiation, and effector responses.
Calmodulin has also been reported by Dong and colleagues to bind the PH domain of Akt family kinases (134). Using short peptide fragments of Akt1 in a pulldown assay, this interaction was further mapped to the first 42 residues of the Akt1 PH domain. Although CaM did not directly alter Akt kinase activity, CaM was reported to reduce the ability of PIP3 to co-precipitate Akt (134), suggesting that CaM competes with PIP3 to dampen Akt activity. However, this finding is inconsistent with other published data demonstrating a requirement for CaM in optimal Akt phosphorylation at T308 and S473 (135, 136). Thus, further investigation is warranted to clarify the functional significance of CaM binding to the AKT PH domain and to determine the precise role of this interaction in lymphocytes.
Conclusion
The studies discussed herein highlight the essential yet complex functions of PH domain-containing proteins in lymphocytes and other immune cells. It is well established that a subset of PH domains modulate the function of their parent proteins by binding to membrane-bound lipids as well as soluble lipid analogs. Furthermore, proteins regulated in this manner, such as the PI3K effector kinases Akt and Itk, are indispensable for immune cell function. Indeed, mutations that disrupt the lipid-binding capacity of PH domains are known to result in human disease, a phenomenon perhaps best demonstrated by the immunologic defects associated with mutations in Tec family kinases. Analogous and unique pathological processes observed in animal models and in vitro experiments reinforce the critical role of PH domain-containing proteins in the immune system. However, evidence increasingly shows that PH domains also interact with non-lipid substrates, and these interactions can be cooperative, antagonistic, or completely independent of lipid-binding capacity. The breadth of these interactions must be elucidated in order to fully understand role of PH domain-containing proteins in immune cell function. Thus, future work should investigate the capacity of PH domains to interact with multiple substrates, including both lipids and proteins, and should include careful evaluation of how binding of each substrate affects the binding of others.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Acknowledgments
This work was supported by NIH grant AI089805 to YH.
References
- 1.Gadina M, Sudarshan C, Visconti R, Zhou YJ, Gu H, Neel BG, et al. The docking molecule gab2 is induced by lymphocyte activation and is involved in signaling by interleukin-2 and interleukin-15 but not other common gamma chain-using cytokines. J Biol Chem (2000) 275:26959–66. 10.1074/jbc.M004021200 [DOI] [PubMed] [Google Scholar]
- 2.Ward SG, Cantrell DA. Phosphoinositide 3-kinases in T lymphocyte activation. Curr Opin Immunol (2001) 13:332–8. 10.1016/S0952-7915(00)00223-5 [DOI] [PubMed] [Google Scholar]
- 3.Koyasu S. The role of PI3K in immune cells. Nat Immunol (2003) 4:313–9. 10.1038/ni0403-313 [DOI] [PubMed] [Google Scholar]
- 4.Guthridge MA, Lopez AF. Phosphotyrosine/phosphoserine binary switches: a new paradigm for the regulation of PI3K signalling and growth factor pleiotropy? Biochem Soc Trans (2007) 35:250–2. 10.1042/BST0350250 [DOI] [PubMed] [Google Scholar]
- 5.Swainson L, Kinet S, Mongellaz C, Sourisseau M, Henriques T, Taylor N. IL-7-induced proliferation of recent thymic emigrants requires activation of the PI3K pathway. Blood (2007) 109:1034–42. 10.1182/blood-2006-06-027912 [DOI] [PubMed] [Google Scholar]
- 6.Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune cells. Annu Rev Immunol (2013) 31:675–704. 10.1146/annurev-immunol-032712-095946 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Billadeau DD, Upshaw JL, Schoon RA, Dick CJ, Leibson PJ. NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway. Nat Immunol (2003) 4:557–64. 10.1038/ni929 [DOI] [PubMed] [Google Scholar]
- 8.Kolsch U, Arndt B, Reinhold D, Lindquist JA, Juling N, Kliche S, et al. Normal T cell development and immune functions in TRIM-deficient mice. Mol Cell Biol (2006) 26:3639–48. 10.1128/MCB.26.9.3639-3648.2006 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Upshaw JL, Arneson LN, Schoon RA, Dick CJ, Billadeau DD, Leibson PJ. NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells. Nat Immunol (2006) 7:524–32. 10.1038/ni1325 [DOI] [PubMed] [Google Scholar]
- 10.Koelsch U, Schraven B, Simeoni L. SIT and TRIM determine T cell fate in the thymus. J Immunol (2008) 181:5930–9. 10.4049/jimmunol.181.9.5930 [DOI] [PubMed] [Google Scholar]
- 11.Laird MH, Rhee SH, Perkins DJ, Medvedev AE, Piao W, Fenton MJ, et al. TLR4/MyD88/PI3K interactions regulate TLR4 signaling. J Leukoc Biol (2009) 85:966–77. 10.1189/jlb.1208763 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol (2010) 11:329–41. 10.1038/nrm2882 [DOI] [PubMed] [Google Scholar]
- 13.Andrews S, Stephens LR, Hawkins PT. PI3K class IB pathway in neutrophils. Sci STKE (2007) 2007:cm3. 10.1126/stke.4072007cm2 [DOI] [PubMed] [Google Scholar]
- 14.Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene (2008) 27:5527–41. 10.1038/onc.2008.247 [DOI] [PubMed] [Google Scholar]
- 15.Insall RH, Weiner OD. PIP3, PIP2, and cell movement – similar messages, different meanings? Dev Cell (2001) 1:743–7. 10.1016/S1534-5807(01)00086-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Wang J, Richards DA. Segregation of PIP2 and PIP3 into distinct nanoscale regions within the plasma membrane. Biol Open (2012) 1:857–62. 10.1242/bio.20122071 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Lemmon MA. Membrane recognition by phospholipid-binding domains. Nat Rev Mol Cell Biol (2008) 9:99–111. 10.1038/nrm2328 [DOI] [PubMed] [Google Scholar]
- 18.Isakoff SJ, Cardozo T, Andreev J, Li Z, Ferguson KM, Abagyan R, et al. Identification and analysis of PH domain-containing targets of phosphatidylinositol 3-kinase using a novel in vivo assay in yeast. EMBO J (1998) 17:5374–87. 10.1093/emboj/17.18.5374 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.De Matteis MA, Di Campli A, Godi A. The role of the phosphoinositides at the golgi complex. Biochim Biophys Acta (2005) 1744:396–405. 10.1016/j.bbamcr.2005.04.013 [DOI] [PubMed] [Google Scholar]
- 20.Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell (2007) 129:1261–74. 10.1016/j.cell.2007.06.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Gonzalez E, McGraw TE. The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle (2009) 8:2502–8. 10.4161/cc.8.16.9335 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Hemmings BA, Restuccia DF. PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol (2012) 4:a011189. 10.1101/cshperspect.a011189 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Limon JJ, Fruman DA. Akt and mTOR in B cell activation and differentiation. Front Immunol (2012) 3:228. 10.3389/fimmu.2012.00228 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Obata T, Yaffe MB, Leparc GG, Piro ET, Maegawa H, Kashiwag A, et al. Peptide and protein library screening defines optimal substrate motifs for AKT/PKB. J Biol Chem (2000) 285:36108–15. 10.1074/jbc.M005497200 [DOI] [PubMed] [Google Scholar]
- 25.Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature (2007) 448:439–44. 10.1038/nature05933 [DOI] [PubMed] [Google Scholar]
- 26.Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 486:405–9. 10.1038/nature11154 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Landgraf KE, Pilling C, Falke JJ. Molecular mechanism of an oncogenic mutation that alters membrane targeting: glu17lys modifies the PIP lipid specificity of the AKT1 PH domain. Biochemistry (2008) 47:12260–9. 10.1021/bi801683k [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Kharas MG, Okabe R, Ganis JJ, Gozo M, Khandan T, Paktinat M, et al. Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood (2010) 115:1406–15. 10.1182/blood-2009-06-229443 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z, et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell (2007) 128:309–23. 10.1016/j.cell.2006.12.029 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Fabre S, Carrette F, Chen J, Lang V, Semichon M, Denoyelle C, et al. FOXO1 regulates L-selectin and a network of human T cell homing molecules downstream of phosphatidylinositol 3-kinase. J Immunol (2008) 181:2980–9. 10.4049/jimmunol.181.5.2980 [DOI] [PubMed] [Google Scholar]
- 31.Kerdiles YM, Beisner DR, Tinoco R, Dejean AS, Castrillon DH, Depinho RA, et al. Foxo1 links homing and survival of naive T cells by regulating L-selectin, CCR7 and interleukin 7 receptor. Nat Immunol (2009) 10:176–84. 10.1038/ni.1689 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Ouyang W, Beckett O, Flavell RA, Li MO. An essential role of the forkhead-box transcription factor Foxo1 in control of T cell homeostasis and tolerance. Immunity (2009) 30:358–71. 10.1016/j.immuni.2009.02.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Merkenschlager M, von Boehmer H. PI3 kinase signalling blocks Foxp3 expression by sequestering foxo factors. J Exp Med (2010) 207:1347–50. 10.1084/jem.20101156 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Ouyang W, Beckett O, Ma Q, Paik JH, Depinho RA, Li MO. Foxo proteins cooperatively control the differentiation of Foxp3+ regulatory T cells. Nat Immunol (2010) 11:618–27. 10.1038/ni.1884 [DOI] [PubMed] [Google Scholar]
- 35.Alkhatib A, Werner M, Hug E, Herzog S, Eschbach C, Faraidun H, et al. FoxO1 induces Ikaros splicing to promote immunoglobulin gene recombination. J Exp Med (2012) 209:395–406. 10.1084/jem.20110216 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Rao RR, Li Q, Gubbels Bupp MR, Shrikant PA. Transcription factor Foxo1 represses T-bet-mediated effector functions and promotes memory CD8(+) T cell differentiation. Immunity (2012) 36:374–87. 10.1016/j.immuni.2012.01.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Michelini RH, Doedens AL, Goldrath AW, Hedrick SM. Differentiation of CD8 memory T cells depends on Foxo1. J Exp Med (2013) 210:1189–200. 10.1084/jem.20130392 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Hedrick SM. The cunning little vixen: foxo and the cycle of life and death. Nat Immunol (2009) 10:1057–63. 10.1038/ni.1784 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Haxhinasto S, Mathis D, Benoist C. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J Exp Med (2008) 205:565–74. 10.1084/jem.20071477 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Pierau M, Engelmann S, Reinhold D, Lapp T, Schraven B, Bommhardt UH. Protein kinase B/Akt signals impair Th17 differentiation and support natural regulatory T cell function and induced regulatory T cell formation. J Immunol (2009) 183:6124–34. 10.4049/jimmunol.0900246 [DOI] [PubMed] [Google Scholar]
- 41.Kim EH, Sullivan JA, Plisch EH, Tejera MM, Jatzek A, Choi KY, et al. Signal integration by Akt regulates CD8 T cell effector and memory differentiation. J Immunol (2012) 188:4305–14. 10.4049/jimmunol.1103568 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Lucas CL, Kuehn HS, Zhao F, Niemela JE, Deenick EK, Palendira U, et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency. Nat Immunol (2014) 15:88–97. 10.1038/ni.2771 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Sukumar M, Liu J, Ji Y, Subramanian M, Crompton JG, Yu Z, et al. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest (2013) 123:4479–88. 10.1172/JCI69589 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Macintyre AN, Finlay D, Preston G, Sinclair LV, Waugh CM, Tamas P, et al. Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism. Immunity (2011) 34:224–36. 10.1016/j.immuni.2011.01.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell (1993) 72:279–90. 10.1016/0092-8674(93)90667-F [DOI] [PubMed] [Google Scholar]
- 46.Afar DE, Park H, Howell BW, Rawlings DJ, Cooper J, Witte ON. Regulation of Btk by Src family tyrosine kinases. Mol Cell Biol (1996) 16:3465–71. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Rawlings DJ, Scharenberg AM, Park H, Wahl MI, Lin S, Kato RM, et al. Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science (1996) 271:822–5. 10.1126/science.271.5250.822 [DOI] [PubMed] [Google Scholar]
- 48.Niiro H, Clark EA. Regulation of B cell fate by antigen-receptor signals. Nat Rev Immunol (2002) 2:945–56. 10.1038/nri955 [DOI] [PubMed] [Google Scholar]
- 49.Vihinen M, Brandau O, Branden LJ, Kwan SP, Lappalainen I, Lester T, et al. BTKbase, mutation database for X-linked agammaglobulinemia (XLA). Nucleic Acids Res (1998) 26:242–7 10.1093/nar/26.1.242 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Vihinen M, Kwan S-P, Lester T, Ochs HD, Resnick I, Väliaho J, et al. Mutations of the human BTK gene coding for Bruton tyrosine kinase in X-linked agammaglobulinemia. Hum Mutat (1999) 13:280–5. [DOI] [PubMed] [Google Scholar]
- 51.Nomura K, Kanegane H, Karasuyama H, Tsukada S, Agematsu K, Murakami G, et al. Genetic defect in human X-linked agammaglobulinemia impedes a maturational evolution of pro-B cells into a later stage of pre-B cells in the B cell differentiation pathway. Blood (2000) 96:610–7. [PubMed] [Google Scholar]
- 52.Fukuda M, Kojima T, Kabayama H, Mikoshiba K. Mutation of the pleckstrin homology domain of Bruton’s tyrosine kinase in immunodeficiency impaired inositol 1,3,4,5-tetrakisphosphate binding capacity. J Biol Chem (1996) 271:30303–6. 10.1074/jbc.271.48.30303 [DOI] [PubMed] [Google Scholar]
- 53.Varnai P, Rother KI, Balla T. Phosphatidylinositol 3-kinase-dependent membrane association of the Bruton’s tyrosine kinase pleckstrin homology domain visualized in single living cells. J Biol Chem (1999) 274:10983–9. 10.1074/jbc.274.16.10983 [DOI] [PubMed] [Google Scholar]
- 54.Li T, Tsukada S, Satterthwaite A, Havlik MH, Park H, Takatsu K, et al. Activation of Bruton’s tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain. Immunity (1995) 2:451–60. 10.1016/1074-7613(95)90026-8 [DOI] [PubMed] [Google Scholar]
- 55.Maas A, Dingjan GM, Grosveld F, Hendriks RW. Early arrest in B cell development in transgenic mice that express the E41K Bruton’s tyrosine kinase mutant under the control of the CD19 promoter region. J Immunol (1999) 162:6526–33. [PubMed] [Google Scholar]
- 56.Huck K, Feyen O, Niehues T, Rüschendorf F, Hübner N, Laws H-J, et al. Girls homozygous for an IL-2–inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. J Clin Invest (2009) 119:1350–8. 10.1172/JCI37901 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Serwas NK, Cagdas D, Ban SA, Bienemann K, Salzer E, Tezcan I, et al. Identification of ITK deficiency as a novel genetic cause of idiopathic CD4+ T cell lymphopenia. Blood (2014) 124:655–7 10.1182/blood-2014-03-564930 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Barton E, Mandal P, Speck SH. Pathogenesis and host control of gammaherpesviruses: lessons from the mouse. Annu Rev Immunol (2011) 29:351–97. 10.1146/annurev-immunol-072710-081639 [DOI] [PubMed] [Google Scholar]
- 59.Andreotti AH, Schwartzberg PL, Joseph RE, Berg LJ. T cell signaling regulated by the Tec family kinase, Itk. Cold Spring Harb Perspect Biol (2010) 2:a002287. 10.1101/cshperspect.a002287 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Grasis JA, Tsoukas CD. Itk: the rheostat of the T cell response. J Signal Transduct (2011) 2011:297868. 10.1155/2011/297868 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Heyeck SD, Wilcox HM, Bunnell SC, Berg LJ. Lck phosphorylates the activation loop tyrosine of the Itk kinase domain and activates Itk kinase activity. J Biol Chem (1997) 272:25401–8. 10.1074/jbc.272.40.25401 [DOI] [PubMed] [Google Scholar]
- 62.Perez-Villar JJ, Kanner SB. Regulated association between the tyrosine kinase Emt/Itk/Tsk and phospholipase-C gamma 1 in human T lymphocytes. J Immunol (1999) 163:6435–41. [PubMed] [Google Scholar]
- 63.Takesono A, Finkelstein LD, Schwartzberg PL. Beyond calcium: new signaling pathways for Tec family kinases. J Cell Sci (2002) 115:3039–48. [DOI] [PubMed] [Google Scholar]
- 64.Fowell DJ, Shinkai K, Liao XC, Beebe AM, Coffman RL, Littman DR, et al. Impaired NFATc translocation and failure of Th2 development in Itk-deficient CD4+ T cells. Immunity (1999) 11:399–409. 10.1016/S1074-7613(00)80115-6 [DOI] [PubMed] [Google Scholar]
- 65.Miller AT, Wilcox HM, Lai Z, Berg LJ. Signaling through Itk promotes T helper 2 differentiation via negative regulation of T-bet. Immunity (2004) 21:67–80. 10.1016/j.immuni.2004.06.009 [DOI] [PubMed] [Google Scholar]
- 66.Au-Yeung BB, Katzman SD, Fowell DJ. Cutting edge: Itk-dependent signals required for CD4+ T cells to exert, but not gain, Th2 effector function. J Immunol (2006) 176:3895–9. 10.4049/jimmunol.176.7.3895 [DOI] [PubMed] [Google Scholar]
- 67.Gomez-Rodriguez J, Sahu N, Handon R, Davidson TS, Anderson SM, Kirby MR, et al. Differential expression of interleukin-17A and -17F is coupled to T cell receptor signaling via inducible T cell kinase. Immunity (2009) 31:587–97. 10.1016/j.immuni.2009.07.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Liao XC, Littman DR. Altered T cell receptor signaling and disrupted T cell development in mice lacking Itk. Immunity (1995) 3:757–69. 10.1016/1074-7613(95)90065-9 [DOI] [PubMed] [Google Scholar]
- 69.Gomez-Rodriguez J, Wohlfert EA, Handon R, Meylan F, Wu JZ, Anderson SM, et al. Itk-mediated integration of T cell receptor and cytokine signaling regulates the balance between Th17 and regulatory T cells. J Exp Med (2014) 211(3):529–43. 10.1084/jem.20131459 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Jain N, Miu B, Jiang JK, Mckinstry KK, Prince A, Swain SL, et al. CD28 and ITK signals regulate autoreactive T cell trafficking. Nat Med (2013) 19:1632–7. 10.1038/nm.3393 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Cuevas B, Lu Y, Watt S, Kumar R, Zhang J, Siminovitch KA, et al. SHP-1 regulates Lck-induced phosphatidylinositol 3-kinase phosphorylation and activity. J Biol Chem (1999) 274:27583–9. 10.1074/jbc.274.39.27583 [DOI] [PubMed] [Google Scholar]
- 72.Bryceson YT, Ljunggren HG. Arrestin NK cell cytotoxicity. Nat Immunol (2008) 9:835–6 10.1038/ni0808-835 [DOI] [PubMed] [Google Scholar]
- 73.Cornall RJ, Cyster JG, Hibbs ML, Dunn AR, Otipoby KL, Clark EA, et al. Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity (1998) 8:497–508. 10.1016/S1074-7613(00)80554-3 [DOI] [PubMed] [Google Scholar]
- 74.Alegre ML, Frauwirth KA, Thompson CB. T cell regulation by CD28 and CTLA-4. Nat Rev Immunol (2001) 1:220–8. 10.1038/35105024 [DOI] [PubMed] [Google Scholar]
- 75.Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol (2013) 14:1212–8. 10.1038/ni.2762 [DOI] [PubMed] [Google Scholar]
- 76.Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol (2004) 173:945–54. 10.4049/jimmunol.173.2.945 [DOI] [PubMed] [Google Scholar]
- 77.Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, et al. CTLA-4 and PD-1 receptors inhibit T cell activation by distinct mechanisms. Mol Cell Biol (2005) 25:9543–53. 10.1128/MCB.25.21.9543-9553.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Lorenz U. SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunol Rev (2009) 228:342–59. 10.1111/j.1600-065X.2008.00760.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.Ugi S, Imamura T, Maegawa H, Egawa K, Yoshizaki T, Shi K, et al. Protein phosphatase 2A negatively regulates insulin’s metabolic signaling pathway by inhibiting Akt (protein kinase B) activity in 3T3-L1 adipocytes. Mol Cell Biol (2004) 24:8778–89. 10.1128/MCB.24.19.8778-8789.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80.Kuo YC, Huang KY, Yang CH, Yang YS, Lee WY, Chiang CW. Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. J Biol Chem (2008) 283:1882–92. 10.1074/jbc.M709585200 [DOI] [PubMed] [Google Scholar]
- 81.Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W, et al. Molecular basis of T cell inactivation by CTLA-4. Science (1998) 282:2263–6. 10.1126/science.282.5397.2263 [DOI] [PubMed] [Google Scholar]
- 82.Huang YH, Sauer K. Lipid signaling in T cell development and function. Cold Spring Harb Perspect Biol (2010) 2:a002428. 10.1101/cshperspect.a002428 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83.Fedele CG, Ooms LM, Ho M, Vieusseux J, O’toole SA, Millar EK, et al. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci U S A (2010) 107:22231–6. 10.1073/pnas.1015245107 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 84.Ono M, Bolland S, Tempst P, Ravetch JV. Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB. Nature (1996) 383:263–6. 10.1038/383263a0 [DOI] [PubMed] [Google Scholar]
- 85.Wang JW, Howson JM, Ghansah T, Desponts C, Ninos JM, May SL, et al. Influence of SHIP on the NK repertoire and allogeneic bone marrow transplantation. Science (2002) 295:2094–7. 10.1126/science.1068438 [DOI] [PubMed] [Google Scholar]
- 86.Newton RH, Turka LA. Regulation of T cell homeostasis and responses by pten. Front Immunol (2012) 3:151. 10.3389/fimmu.2012.00151 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87.Sauer K, Cooke MP. Regulation of immune cell development through soluble inositol-1,3,4,5-tetrakisphosphate. Nat Rev Immunol (2010) 10:257–71. 10.1038/nri2745 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88.Pouillon V, Hascakova-Bartova R, Pajak B, Adam E, Bex F, Dewaste V, et al. Inositol 1,3,4,5-tetrakisphosphate is essential for T lymphocyte development. Nat Immunol (2003) 4:1136–43. 10.1038/ni980 [DOI] [PubMed] [Google Scholar]
- 89.Wen BG, Pletcher MT, Warashina M, Choe SH, Ziaee N, Wiltshire T, et al. Inositol (1,4,5) trisphosphate 3 kinase B controls positive selection of T cells and modulates Erk activity. Proc Natl Acad Sci U S A (2004) 101:5604–9. 10.1073/pnas.0306907101 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 90.Marechal Y, Pesesse X, Jia Y, Pouillon V, Perez-Morga D, Daniel J, et al. Inositol 1,3,4,5-tetrakisphosphate controls proapoptotic Bim gene expression and survival in B cells. Proc Natl Acad Sci U S A (2007) 104:13978–83. 10.1073/pnas.0704312104 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 91.Miller AT, Sandberg M, Huang YH, Young M, Sutton S, Sauer K, et al. Production of Ins(1,3,4,5)P4 mediated by the kinase Itpkb inhibits store-operated calcium channels and regulates B cell selection and activation. Nat Immunol (2007) 8:514–21. 10.1038/ni1458 [DOI] [PubMed] [Google Scholar]
- 92.Miller AT, Beisner DR, Liu D, Cooke MP. Inositol 1,4,5-trisphosphate 3-kinase B is a negative regulator of BCR signaling that controls B cell selection and tolerance induction. J Immunol (2009) 182:4696–704. 10.4049/jimmunol.0802850 [DOI] [PubMed] [Google Scholar]
- 93.Huang YH, Grasis JA, Miller AT, Xu R, Soonthornvacharin S, Andreotti AH, et al. Positive regulation of Itk PH domain function by soluble IP4. Science (2007) 316:886–9. 10.1126/science.1138684 [DOI] [PubMed] [Google Scholar]
- 94.Jia Y, Subramanian KK, Erneux C, Pouillon V, Hattori H, Jo H, et al. Inositol 1,3,4,5-tetrakisphosphate negatively regulates phosphatidylinositol-3,4,5-trisphosphate signaling in neutrophils. Immunity (2007) 27:453–67. 10.1016/j.immuni.2007.07.016 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 95.Sauer K, Park E, Siegemund S, French AR, Wahle JA, Sternberg L, et al. Inositol tetrakisphosphate limits NK cell effector functions by controlling PI3K signaling. Blood (2013) 121:286–97. 10.1182/blood-2012-05-429241 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 96.Chakraborty A, Koldobskiy MA, Bello NT, Maxwell M, Potter JJ, Juluri KR, et al. Inositol pyrophosphates inhibit Akt signaling, thereby regulating insulin sensitivity and weight gain. Cell (2010) 143:897–910. 10.1016/j.cell.2010.11.032 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 97.Saiardi A, Erdjument-Bromage H, Snowman AM, Tempst P, Snyder SH. Synthesis of diphosphoinositol pentakisphosphate by a newly identified family of higher inositol polyphosphate kinases. Curr Biol (1999) 9:1323–6. 10.1016/S0960-9822(00)80055-X [DOI] [PubMed] [Google Scholar]
- 98.Manning BD. Insulin signaling: inositol phosphates get into the Akt. Cell (2010) 143:861–3. 10.1016/j.cell.2010.11.040 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 99.Prasad A, Jia Y, Chakraborty A, Li Y, Jain SK, Zhong J, et al. Inositol hexakisphosphate kinase 1 regulates neutrophil function in innate immunity by inhibiting phosphatidylinositol-(3,4,5)-trisphosphate signaling. Nat Immunol (2011) 12:752–60. 10.1038/ni.2052 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 100.Luo HR, Huang YE, Chen JC, Saiardi A, Iijima M, Ye K, et al. Inositol pyrophosphates mediate chemotaxis in dictyostelium via pleckstrin homology domain-PtdIns(3,4,5)P3 interactions. Cell (2003) 114:559–72. 10.1016/S0092-8674(03)00640-8 [DOI] [PubMed] [Google Scholar]
- 101.Wang Q, Vogan EM, Nocka LM, Rosen CE, Zorn JA, Harrison SC, et al. Autoinhibition of Bruton’s tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate. Elife (2015). 10.7554/eLife.06074 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 102.Park WS, Heo WD, Whalen JH, O’rourke NA, Bryan HM, Meyer T, et al. Comprehensive identification of PIP3-regulated PH domains from C. elegans to H. sapiens by model prediction and live imaging. Mol Cell (2008) 30:381–92. 10.1016/j.molcel.2008.04.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 103.Feske S. Calcium signalling in lymphocyte activation and disease. Nat Rev Immunol (2007) 7:690–702. 10.1038/nri2152 [DOI] [PubMed] [Google Scholar]
- 104.Fu G, Chen Y, Yu M, Podd A, Schuman J, He Y, et al. Phospholipase C{gamma}1 is essential for T cell development, activation, and tolerance. J Exp Med (2010) 207:309–18. 10.1084/jem.20090880 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 105.Wang D, Feng J, Wen R, Marine JC, Sangster MY, Parganas E, et al. Phospholipase Cgamma2 is essential in the functions of B cell and several Fc receptors. Immunity (2000) 13:25–35. 10.1016/S1074-7613(00)00005-4 [DOI] [PubMed] [Google Scholar]
- 106.Wen R, Jou ST, Chen Y, Hoffmeyer A, Wang D. Phospholipase C gamma 2 is essential for specific functions of Fc epsilon R and Fc gamma R. J Immunol (2002) 169:6743–52. 10.4049/jimmunol.169.12.6743 [DOI] [PubMed] [Google Scholar]
- 107.Graham DB, Robertson CM, Bautista J, Mascarenhas F, Diacovo MJ, Montgrain V, et al. Neutrophil-mediated oxidative burst and host defense are controlled by a Vav-PLCgamma2 signaling axis in mice. J Clin Invest (2007) 117:3445–52. 10.1172/JCI32729 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 108.Falasca M, Logan SK, Lehto VP, Baccante G, Lemmon MA, Schlessinger J. Activation of phospholipase C gamma by PI 3-kinase-induced PH domain-mediated membrane targeting. EMBO J (1998) 17:414–22. 10.1093/emboj/17.2.414 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 109.Rhee SG, Bae YS. Regulation of phosphoinositide-specific phospholipase C isozymes. J Biol Chem (1997) 272:15045–8 10.1074/jbc.272.24.15045 [DOI] [PubMed] [Google Scholar]
- 110.Rhee SG. Regulation of phosphoinositide-specific phospholipase C. Annu Rev Biochem (2001) 70:281–312 10.1146/annurev.biochem.70.1.281 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 111.Kim SK, Wee SM, Chang JS, Kwon TK, Min DS, Lee YH, et al. Point mutations in the split PLC-gamma1 PH domain modulate phosphoinositide binding. J Biochem Mol Biol (2004) 37:720–5. 10.5483/BMBRep.2004.37.6.720 [DOI] [PubMed] [Google Scholar]
- 112.Lemmon MA. Pleckstrin homology domains: two halves make a hole? Cell (2005) 120:574–6. 10.1016/j.cell.2005.02.023 [DOI] [PubMed] [Google Scholar]
- 113.van Rossum DB, Patterson RL, Sharma S, Barrow RK, Kornberg M, Gill DL, et al. Phospholipase Cgamma1 controls surface expression of TRPC3 through an intermolecular PH domain. Nature (2005) 434:99–104. 10.1038/nature03340 [DOI] [PubMed] [Google Scholar]
- 114.Piechulek T, Rehlen T, Walliser C, Vatter P, Moepps B, Gierschik P. Isozyme-specific stimulation of phospholipase C-gamma2 by Rac GTPases. J Biol Chem (2005) 280:38923–31. 10.1074/jbc.M509396200 [DOI] [PubMed] [Google Scholar]
- 115.Walliser C, Retlich M, Harris R, Everett KL, Josephs MB, Vatter P, et al. Rac regulates its effector phospholipase Cgamma2 through interaction with a split pleckstrin homology domain. J Biol Chem (2008) 283:30351–62. 10.1074/jbc.M803316200 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 116.Everett KL, Buehler A, Bunney TD, Margineanu A, Baxendale RW, Vatter P, et al. Membrane environment exerts an important influence on Rac-mediated activation of phospholipase Cgamma2. Mol Cell Biol (2011) 31:1240–51. 10.1128/MCB.01408-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 117.Calleja V, Laguerre M, Parker PJ, Larijani B. Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition. PLoS Biol (2009) 7:e17. 10.1371/journal.pbio.1000017 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 118.Wu WI, Voegtli WC, Sturgis HL, Dizon FP, Vigers GP, Brandhuber BJ. Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition. PLoS One (2010) 5:e12913. 10.1371/journal.pone.0012913 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 119.Parikh C, Janakiraman V, Wu WI, Foo CK, Kljavin NM, Chaudhuri S, et al. Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers. Proc Natl Acad Sci U S A (2012) 109:19368–73. 10.1073/pnas.1204384109 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 120.Fischer KD, Zmuldzinas A, Gardner S, Barbacid M, Bernstein A, Guidos C. Defective T cell receptor signalling and positive selection of Vav-deficient CD4+ CD8+ thymocytes. Nature (1995) 374:474–7. 10.1038/374474a0 [DOI] [PubMed] [Google Scholar]
- 121.Tedford K, Nitschke L, Girkontaite I, Charlesworth A, Chan G, Sakk V, et al. Compensation between Vav-1 and Vav-2 in B cell development and antigen receptor signaling. Nat Immunol (2001) 2:548–55. 10.1038/88756 [DOI] [PubMed] [Google Scholar]
- 122.Turner M, Billadeau DD. VAV proteins as signal integrators for multi-subunit immune-recognition receptors. Nat Rev Immunol (2002) 2:476–86. 10.1038/nri840 [DOI] [PubMed] [Google Scholar]
- 123.Hall AB, Gakidis MA, Glogauer M, Wilsbacher JL, Gao S, Swat W, et al. Requirements for Vav guanine nucleotide exchange factors and Rho GTPases in FcgammaR- and complement-mediated phagocytosis. Immunity (2006) 24:305–16. 10.1016/j.immuni.2006.02.005 [DOI] [PubMed] [Google Scholar]
- 124.Han J, Luby-Phelps K, Das B, Shu X, Xia Y, Mosteller RD, et al. Role of substrates and products of PI 3-kinase in regulating activation of Rac-related guanosine triphosphatases by Vav. Science (1998) 279:558–60. 10.1126/science.279.5350.558 [DOI] [PubMed] [Google Scholar]
- 125.Ma AD, Metjian A, Bagrodia S, Taylor S, Abrams CS. Cytoskeletal reorganization by G protein-coupled receptors is dependent on phosphoinositide 3-kinase gamma, a Rac guanosine exchange factor, and Rac. Mol Cell Biol (1998) 18:4744–51. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 126.Li P, Martins IR, Amarasinghe GK, Rosen MK. Internal dynamics control activation and activity of the autoinhibited Vav DH domain. Nat Struct Mol Biol (2008) 15:613–8. 10.1038/nsmb.1428 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 127.Yu B, Martins IR, Li P, Amarasinghe GK, Umetani J, Fernandez-Zapico ME, et al. Structural and energetic mechanisms of cooperative autoinhibition and activation of Vav1. Cell (2010) 140:246–56. 10.1016/j.cell.2009.12.033 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 128.Kranewitter WJ, Gimona M. N-terminally truncated Vav induces the formation of depolymerization-resistant actin filaments in NIH 3T3 cells. FEBS Lett (1999) 455:123–9. 10.1016/S0014-5793(99)00857-1 [DOI] [PubMed] [Google Scholar]
- 129.Das B, Shu X, Day GJ, Han J, Krishna UM, Falck JR, et al. Control of intramolecular interactions between the pleckstrin homology and Dbl homology domains of Vav and Sos1 regulates Rac binding. J Biol Chem (2000) 275:15074–81. 10.1074/jbc.M907269199 [DOI] [PubMed] [Google Scholar]
- 130.Rossman KL, Der CJ, Sondek J. GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol (2005) 6:167–80. 10.1038/nrm1587 [DOI] [PubMed] [Google Scholar]
- 131.Aghazadeh B, Lowry WE, Huang X-Y, Rosen MK. Structural basis for relief of autoinhibition of the Dbl homology domain of proto-oncogene Vav by tyrosine phosphorylation. Cell (2000) 102:625–33. 10.1016/S0092-8674(00)00085-4 [DOI] [PubMed] [Google Scholar]
- 132.Rossman KL, Worthylake DK, Snyder JT, Siderovski DP, Campbell SL, Sondek J. A crystallographic view of interactions between Dbs and Cdc42: pH domain-assisted guanine nucleotide exchange. EMBO J (2002) 21:1315–26. 10.1093/emboj/21.6.1315 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 133.Wang X, Boyken SE, Hu J, Xu X, Rimer RP, Shea MA, et al. Calmodulin and PI(3,4,5)P(3) cooperatively bind to the Itk pleckstrin homology domain to promote efficient calcium signaling and IL-17A production. Sci Signal (2014) 7:ra74. 10.1126/scisignal.2005147 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 134.Dong B, Valencia CA, Liu R. Ca(2+)/calmodulin directly interacts with the pleckstrin homology domain of AKT1. J Biol Chem (2007) 282:25131–40. 10.1074/jbc.M702123200 [DOI] [PubMed] [Google Scholar]
- 135.Deb TB, Coticchia CM, Dickson RB. Calmodulin-mediated activation of Akt regulates survival of c-Myc-overexpressing mouse mammary carcinoma cells. J Biol Chem (2004) 279:38903–11. 10.1074/jbc.M405314200 [DOI] [PubMed] [Google Scholar]
- 136.Coticchia CM, Revankar CM, Deb TB, Dickson RB, Johnson MD. Calmodulin modulates Akt activity in human breast cancer cell lines. Breast Cancer Res Treat (2009) 115:545–60. 10.1007/s10549-008-0097-z [DOI] [PMC free article] [PubMed] [Google Scholar]